Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
NCT ID: NCT00479505
Last Updated: 2011-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
275 participants
INTERVENTIONAL
2007-06-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
NCT00408954
Urge Incontinence Bladder Overactivity Study
NCT00475696
Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity
NCT00335660
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
NCT00290563
Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)
NCT01799902
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
UK-369,003
UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UK-369,003
UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* documented clinical diagnosis of overactive bladder with urinary frequency \>= 8 times / 24 hours and number of urgency episodes \> 1 episode / 24 hours.
Exclusion Criteria
* Urinary tract infection.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Miranda, New South Wales, Australia
Pfizer Investigational Site
Kippa-Ring, Queensland, Australia
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Barrie, Ontario, Canada
Pfizer Investigational Site
Kitchener, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Rancagua, Región del Libertador General Bernardo O’Higgins, Chile
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Santiago, RM, Chile
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Helsinki, , Finland
Pfizer Investigational Site
Kouvola, , Finland
Pfizer Investigational Site
Oulu, , Finland
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Turku, , Finland
Pfizer Investigational Site
Garches, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Montpellier, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Marburg, , Germany
Pfizer Investigational Site
Muelheim A.d. Ruhr, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Rosenheim, , Germany
Pfizer Investigational Site
Cholargós, Athens, Greece
Pfizer Investigational Site
Epirus, Ioannina, Greece
Pfizer Investigational Site
Rio, Patras, Greece
Pfizer Investigational Site
Cefalù, Palermo, Italy
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Latina, , Italy
Pfizer Investigational Site
Riga, , Latvia
Pfizer Investigational Site
Moelv, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Mysłowice, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Szczecin, , Poland
Pfizer Investigational Site
Szczecin, , Poland
Pfizer Investigational Site
Szczecin, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
Bratislava, Slovakia, Slovakia
Pfizer Investigational Site
Martin, Slovakia, Slovakia
Pfizer Investigational Site
Trenčín, Slovakia, Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Sabadell, Barcelona, Spain
Pfizer Investigational Site
Manacor, Palma de Mallorca, Spain
Pfizer Investigational Site
Aarau, , Switzerland
Pfizer Investigational Site
Zurich, , Switzerland
Pfizer Investigational Site
High Heaton, Newcastle upon Tyne, United Kingdom
Pfizer Investigational Site
Taunton, Somerset, United Kingdom
Pfizer Investigational Site
Leeds, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3711047
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.